NASDAQ
17.07.26 | 21:59
7,540 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.06. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Shattuck Labs drops 6%, prices $75M share raise at $4 per share | 1 | Seeking Alpha | ||
| 10.06. | Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr | 276 | AFX News | WASHINGTON (dpa-AFX) - Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares... ► Artikel lesen | |
| 10.06. | Shattuck Labs prices $75M public offering at $4 per share | 1 | Investing.com | ||
| 10.06. | Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.06. | Shattuck Labs commences public offering of common stock | 2 | Investing.com | ||
| 09.06. | Shattuck Labs launches proposed public offering of common stock | 1 | Seeking Alpha | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 09.06. | Shattuck Labs, Inc. Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.06. | Shattuck Labs receives $54.9M from warrant exercises | 1 | Investing.com | ||
| 09.06. | Shattuck Labs secures $54.9M from warrant exercises, extends cash runway into 2029 | 1 | Seeking Alpha | ||
| 09.06. | Shattuck Labs, Inc.: Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update | 187 | GlobeNewswire (Europe) | AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class... ► Artikel lesen | |
| 08.06. | Why Is Shattuck Labs Stock Trading Lower On Monday? | 1 | Benzinga.com | ||
| 08.06. | Shattuck Labs reports phase 1 data for DR3 blocking antibody | 1 | Investing.com | ||
| 08.06. | Shattuck Labs, Inc.: Shattuck Labs Announces Phase 1 Results for SL-325 | 654 | GlobeNewswire (Europe) | Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of... ► Artikel lesen | |
| 05.06. | Shattuck Labs to present phase 1 data for SL-325 on Monday | 3 | Investing.com | ||
| 05.06. | Shattuck Labs: Vorstellung von Phase-1-Studiendaten zu SL-325 am Montag | 1 | Investing.com Deutsch | ||
| 05.06. | Shattuck Labs, Inc.: Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 | 2 | GlobeNewswire (USA) | ||
| 02.06. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | Shattuck Labs GAAP EPS of -$0.13 in-line | 2 | Seeking Alpha | ||
| 07.05. | Shattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights | 370 | GlobeNewswire (Europe) | Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 -Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,146 | -2,94 % | BRANDMELDUNG bei Valneva: Warum Insider bereits massiv kaufen - So reagieren erfahrene Anleger jetzt | ||
| VIVOSIM LABS | 0,580 | 0,00 % | VivoSim Labs, Inc.: VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 | SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,170 | -2,09 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,294 | -9,54 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| SAREPTA THERAPEUTICS | 15,000 | -0,40 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ARROWHEAD PHARMACEUTICALS | 63,88 | +2,40 % | This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | ||
| ONCO-INNOVATIONS | 0,385 | -1,28 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| REVOLUTION MEDICINES | 163,45 | +4,37 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| TRAWS PHARMA | 0,670 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| VERASTEM | 5,090 | +0,47 % | RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) | ||
| UNIQURE | 34,900 | +1,45 % | uniQure - QURE: Ist das die nächste Kursrakete im Biotech-Sektor?! | Gentherapie-Spezialist! Spekulativer Biotech-Wert mit hoher Volatilität: uniQure-Aktie (QURE) - Fokus auf Studienergebnisse, Zulassungen und regulatorischen Entscheidungen! uniQure (QURE) - IL0011559904... ► Artikel lesen | |
| TRINITY BIOTECH | 0,345 | -6,91 % | Trinity Biotech plc: Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling | - Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,100 | -6,04 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,722 | +3,26 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 2,740 | +1,48 % | Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update | Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular... ► Artikel lesen |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 7,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.